Optometrists in Fort Gibson, OK Accepting Medicare
4 Optometrists found. Showing 1 - 4
 Debbie S. Coy, O.d. P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 330 E Highway 62, Fort Gibson, OK 74434 Phone: 918-478-8888 Fax: 918-478-3465 |
 Debbie S Coy, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 330 E Highway 62, Fort Gibson, OK 74434 Phone: 918-478-8888 Fax: 918-478-3465 |
Warner Family Eye Care Inc Optometrist Medicare: Medicare Enrolled Practice Location: 330 W Highway 62, Fort Gibson, OK 74434 Phone: 918-478-8888 Fax: 918-478-8888 |
Dr. Kimberly Dawn Durossette, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 330 W Highway 62, Fort Gibson, OK 74434 Phone: 918-478-8888 Fax: 918-478-3465 |
News Archive
Bioidentical hormone facts and perspectives
Public confusion of the benefits and risks of hormone therapy was highlighted once again this week on The Oprah Winfrey Show.
UC Davis team refines cancer treatments to reduce potential nerve damage
While radiation treatments deliver precise doses of high-energy X-rays to stop cancer cells from spreading or to shrink tumors, oncologists have become increasingly concerned about inadvertent exposures during head and neck cancer treatments to nerves responsible for upper body mobility.
Caesarean sections do not reduce hepatitis C transmission
Planned Caesarean sections do not help to reduce the chances of a pregnant mother with Hepatitis C (HCV) transmitting the infection to her unborn baby, according to new scientific findings by the National Maternity Hospital in Dublin and University College Dublin.
NanoString's nCounter CNV CodeSets help detect genetic copy number variations
NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.
Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
› Verified 8 days ago
Occupational Therapists
Speech-Language Pathologists
Optometrists
Chiropractors
Physical Therapists